NOVARTIS

DelveInsight's report on Homozygous Familial Hypercholesterolemia (HoFH) forecasts market growth, driven by increasing prevalence and new therapies. The 7MM saw 2,845 HoFH cases in 2022, expected to rise by 2034. Key companies like Novartis and Sanofi are developing treatments targeting LDL-C reduction, with the market valued at USD 108 million in 2022.

Switzerland excels in life sciences due to its strong regional hubs like Basel, Zurich, and Geneva/Lausanne, fostering innovation through bioparks and collaboration between academia and industry. This ecosystem supports start-ups and attracts global talent, maintaining Switzerland's leadership in drug discovery and biotech advancements.

The "Dementia - Global Clinical Trials Review, 2024" report offers an overview of dementia clinical trials globally, including data by region, country, phase, status, and sponsor type. It highlights enrollment trends, key companies, and drugs in ongoing trials, aiding strategic decision-making and identifying business opportunities.

Kashiv BioSciences announced an exclusive licensing agreement with Amneal Pharmaceuticals for ADL018, a biosimilar to omalizumab (XOLAIR®), targeting conditions like severe asthma and chronic urticaria. ADL018 is in Phase III trials, building on Kashiv's success with RELEUKO® & FYLNETRA®. The partnership aims to expand Amneal's biosimilar portfolio beyond oncology, focusing on affordable biologics.

The 9th annual CRAACO® conference, focusing on integrating clinical research with care to enhance trial participation and health outcomes, will be held on September 16, 2024, in Philadelphia. It aims to unite stakeholders to improve access to clinical trials, especially in underserved areas, and discuss the convergence of clinical care and research.

Oncology leads 2024's planned and completing clinical trials, with Pain and Solid Tumor as top indications. Phase II trials dominate, with industry-sponsored trials led by Novartis. Non-industry sponsors, especially the University of Texas MD Anderson Cancer Center, lead in trials estimated to complete in 2024, with APAC having the most such trials.

Novartis projects over $3 billion in peak sales for Scemblix, its new CML treatment, due to its superior efficacy and safety profile. Scemblix has received FDA breakthrough therapy designation and is nearing approval, with Novartis focusing on broad access and physician engagement for a successful launch.

DelveInsight's report on Tenosynovial Giant Cell Tumors (TSGCTs) forecasts market growth to 2034, highlighting epidemiology, treatment trends, and key therapies. The market, valued at USD 300 million in 2023, is driven by increasing prevalence and new therapies like emactuzumab. Localized TGCT cases dominate, with significant growth expected in the 7MM.

Novartis' Scemblix, a TKI therapy, showed superior efficacy in treating Ph+ CML in the Phase III ASC4FIRST trial, with a 67.7% MMR rate at week 48, compared to 49% with SoC TKIs. It also demonstrated better safety, with lower AE rates. Scemblix generated $136m in Q1 sales, with projected sales of $2.4bn by 2030.

Scemblix® (asciminib) showed superior MMR rates at week 48 vs. standard TKIs (67.7% vs. 49.0%) and imatinib alone (69.3% vs. 40.2%) in the Phase III ASC4FIRST trial, with a favorable safety profile. It's a promising frontline treatment for newly diagnosed Ph+ CML-CP patients.